STOCK TITAN
  1. Home
  2. News
  3. SYRS

Syros Pharmaceuticals Inc. - SYRS STOCK NEWS

Welcome to our dedicated news page for Syros Pharmaceuticals (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syros Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syros Pharmaceuticals's position in the market.

News
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Rhea-AI Summary
Syros Pharmaceuticals receives Fast Track Designation from FDA for tamibarotene in combination with azacitidine and venetoclax for newly diagnosed AML patients with RARA overexpression. Positive results from SELECT-AML-1 trial show 100% CR/CRi rate with no added toxicity, potentially offering a new frontline treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
clinical trial
-
News
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ:SYRS) granted 8,400 shares of restricted stock units to a new employee as an inducement for employment. The RSU award vests over several years, subject to continued service with Syros.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
none
-
News
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) completes enrollment of 190 patients for primary endpoint analysis in SELECT-MDS-1 Phase 3 Trial, with pivotal CR data expected by mid-4Q 2024. Additional data from SELECT-AML-1 Phase 2 Trial also anticipated in 2024. The company completed a $45.0 million equity offering, extending cash runway into 2Q 2025. Management to host a conference call today at 8:30 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
earnings
News
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Rhea-AI Summary
Syros Pharmaceuticals completes enrollment of 190 patients in Phase 3 clinical trial for tamibarotene in HR-MDS patients with RARA gene overexpression, on track to report pivotal data by mid-4Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
clinical trial
-
News
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) to report Q4 and full year 2023 financial results and host conference call on March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
-
News
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Syros Pharmaceuticals CEO to Participate in Panel Discussion at TD Cowen 44th Annual Health Care Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences
News
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) is on track to complete enrollment of 190 patients for primary analysis in the SELECT-MDS-1 Phase 3 trial in 1Q 2024. Pivotal CR data is expected by mid-4Q 2024. Additional data from the SELECT-AML-1 Phase 2 trial is also expected in 2024, with initial data demonstrating a 100% CR/CRi rate and a strengthened balance sheet with gross proceeds of approximately $45.0 million from recent equity financing, extending cash runway into 2Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
News
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) announces pricing of underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $45.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.93%
Tags
offering
-
News
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ: SYRS) announced strong initial data from its SELECT-AML-1 Phase 2 trial evaluating tamibarotene, venetoclax, and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The primary endpoint of complete response rate (CR)/complete response with incomplete hematologic recovery (CRi) was 100% among patients treated with the triplet regimen compared to 70% in patients treated with venetoclax and azacitidine alone. Additional data is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.55%
Tags
clinical trial
News
Syros to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) management will participate in fireside chats at the Piper Sandler 35th Annual Healthcare Conference and the JMP Securities Hematology and Oncology Summit. The webcasts and archived recordings will be available on the Syros website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
Stock SYRS logo
Syros Pharmaceuticals Inc.

Nasdaq:SYRS

SYRS Rankings

#4039 Ranked by Market Cap
#4660 Ranked by Stock Gains
N/A Ranked by Dividends

SYRS Stock Data

142.59M
11.26M
1.08%
81.44%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SYRS

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.